Beijing: China has reportedly approved patent for CanSino Biologics Inc’s COVID-19 vaccine — Ad5-nCOV. It is the first patent granted by China for a COVID-19 vaccine.
Saudi Arabia will be carrying out the Phase-III clinical trials for the CanSino vaccine this month.
CanSino is exploring testing the vaccine in Russia, Brazil and Chile as well. CanSino’s Hong Kong shares rose by around 14 per cent on Monday.
Also Read: First Batch Of Russian COVID-19 Vaccine To Roll Out This Month
Comments are closed.